The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index; 194 of the 302 sources its claims cite were checked for support.
Epidemiology of Invasive Candidiasis
Open accessAbstract
Invasive candidiasis (IC) is an increasingly prevalent, costly, and potentially fatal infection brought on by the opportunistic yeast, Candida . Previously, IC has predominantly been caused by C. albicans which is often drug susceptible. There has been a global trend towards decreasing rates of infection secondary to C. albicans and a rise in non- albicans species with a corresponding increase in drug resistance creating treatment challenges. With advances in management of malignancies, there has also been an increase in the population at risk from IC along with a corresponding increase in incidence of breakthrough IC infections. Additionally, the emergence of C. auris creates many challenges in management and prevention due to drug resistance and the organism’s ability to transmit rapidly in the healthcare setting. While the development of novel antifungals is encouraging for future management, understanding the changing epidemiology of IC is a vital step in future management and prevention. Keywords: Candida, epidemiology, resistance, emerging, non- albicans Candida species
Overview
CoChat Summary
TL;DR
Invasive candidiasis remains a costly, morbid, and often fatal infection, with declining *C. albicans* proportions, rising non-albicans species, antifungal resistance, breakthrough infections, and the emergence of multidrug-resistant *C. auris*. This review synthesizes global epidemiology, diagnostics, burden, species distribution, resistance trends, management, and prevention.
Key findings
- Candidemia causes an estimated 22,000 infections annually in the United States and is the second most common healthcare-associated bloodstream infection nationally; all-cause in-hospital mortality has been reported as high as 36% in the US, 38–42% at 30 days in Europe, ~40% in Asia, 33–60% in MENA, and 30–70% in South America.
- The proportion of *C. albicans* has fallen from 70–80% in the 1980–1990s to 40–60% in most areas; in ECMM studies, *C. albicans* decreased from 56.4% (1997–1999) to 54% (2006–2008) to 46.0% (2018), while *C. glabrata* rose from 13.9% to 21.0%.
- Resistance is increasing: CDC surveys report *C. glabrata* fluconazole resistance of 7–11% and echinocandin resistance of 2–8%; *C. parapsilosis* fluconazole resistance exceeds 50% in some series and is 4–10% in the US; *C. auris* shows fluconazole resistance in 70–90% of isolates, echinocandin resistance up to 7%, amphotericin B resistance up to 35%, and pan-resistance most commonly in India/South Asia (3%).
- Breakthrough *Candida* infections occur in fewer than 10% of at-risk patients but can constitute up to 40% of all *Candida* infections in selected series; 30-day mortality is similar to de novo infections (~30%). Blood cultures have only ~50% sensitivity for invasive candidiasis; T2Candida has 91% sensitivity and 94% specificity, while 1,3-β-D-glucan sensitivity averages ~85% but specificity is often below 60%.
Methods
- Narrative review of invasive candidiasis epidemiology, diagnostics, burden, geographic species differences, emerging species, breakthrough infections, antifungal susceptibility, management, antifungal pipeline, and infection control.
- Evidence is drawn from published literature, including population-based surveillance, meta-analyses, multicenter ECMM/SENTRY/CDC/TRANSNET studies, clinical trials, and guidelines; no new primary data are presented.
- Main analysis is qualitative synthesis; no systematic review search strategy, risk-of-bias assessment, or quantitative pooling is described.
Limitations
- Stated: current diagnostics have limited sensitivity/specificity that affect epidemiologic assessment; intra-abdominal candidiasis lacks standardized definitions; there are no population-based data sources for Asia, the Middle East, Africa, or Latin America; most IC studies are single-center or smaller multicenter analyses; candidemia is generally not reportable, so reporting is voluntary; lack of standardized methodologies and denominators limits comparisons.
- Stated: the overall burden of IC is likely underestimated because of global surveillance gaps and diagnostic performance limitations.
- Evident: as a narrative review, it does not provide a systematic search, formal quality appraisal, or quantitative synthesis, so conclusions may inherit publication and surveillance biases from the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
104 Valid · 10 Not valid · 40 Not checked · 16 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Partly supportedcites [122] Lockhart, 2017, Clin Infect Dis sourceExperimental — accuracy not yet measured
The Results (Antifungal Susceptibility Testing; page unavailable) report that the two isolates resistant to all three major antifungal classes were both from India, supporting the geographic comparison within this study’s sample. The paper reports 4% of all tested isolates—not 3% of Indian isolates—and its samples from four countries do not establish how common this resistance is worldwide. (LLM, conf=0.88)
- Partly supportedcites [123] Chowdhary, 2017, PLoS Pathog sourceExperimental — accuracy not yet measured
In “Is antifungal resistance in C. auris a therapeutic challenge?” (page unavailable), the paper reports that a low number (4%) of isolates resist all antifungal classes. It does not give the claimed 3% figure for India or establish that resistance to all three classes is less common elsewhere. (LLM, conf=0.84)
- Disputedcites [124] Chowdhary, 2018, J Antimicrob Chemother sourceExperimental — accuracy not yet measured
The JAC section reports that 2% of the Indian isolates had combined azole and echinocandin resistance. Resistance to all three classes could not therefore occur in 3% of those isolates. The Discussion’s 3% figure refers to echinocandin resistance alone among US isolates, and the paper does not establish that triple-class resistance is most common in India. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Results sections report fluconazole resistance in C. tropicalis isolates, including 9.2% in the Asia-Pacific region, and echinocandin resistance of 0.5%–0.7% during the surveillance period. That contradicts pan-susceptibility across those drug classes. The Methods list the agents tested and do not include amphotericin B, so the paper does not establish that part of the claim. The supplied copy gives section labels but no page numbers. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
Table 4 (Results, Fluconazole Resistance by Geographic Area and Species) reports 3.7% fluconazole resistance for North American C. parapsilosis isolates in 2006–2016, rather than a US rate of 4–10%. It reports 4.6% in Europe and 4.3% in Latin America—only slightly above the North American rate, not much higher. The table does not give a separate rate for Japan. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Could not verifycites [103] Adam, 2021, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Antifungal Susceptibility Testing section reports 4%–7% fluconazole nonsusceptibility in C. parapsilosis isolates from Switzerland, not resistance rates in the US. A search for US C. parapsilosis fluconazole resistance rates found no passage giving the claimed 4%–10% range. (LLM, conf=0.76)
- Partly supportedcites [112] Arastehfar, 2020, J Fungi sourceExperimental — accuracy not yet measured
Section 6.3 reports fluconazole-resistant C. parapsilosis, and section 9 says it has been observed in the USA. Neither passage gives a US resistance rate of 4–10%; the percentages in section 6.3 refer to other regions. (LLM, conf=0.83)
- Could not verifycites [120] Pfaller, 2011, J Clin Microbiol sourceExperimental — accuracy not yet measured
The Results and Discussion passages report susceptibility of Aspergillus species to itraconazole, posaconazole, and voriconazole; page numbers are unavailable in our copy. Searches for fluconazole, C. parapsilosis, and the stated geographic comparison found no passage reporting the claimed US resistance rate. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Results (Table 4; page not provided) report C. parapsilosis fluconazole resistance of 3.7% in North America, 4.6% in Europe, 4.3% in Latin America, and 0.6% in Asia-Pacific. Europe and Latin America are only slightly higher than North America, while Asia-Pacific is lower—not the much higher rates claimed. The table does not give separate rates for the US, Japan, or Western Europe. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [103] Adam, 2021, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Discussion says several countries have reported emerging azole resistance in C. parapsilosis. However, it does not identify Japan, Western Europe, or Latin America or compare their fluconazole resistance rates with those in the US. The susceptibility-testing section reports Swiss nonsusceptibility rates of 6%, 7%, and 4% across the study periods, not the claimed international comparison. (LLM, conf=0.76)
- Disputedcites [112] Arastehfar, 2020, J Fungi sourceExperimental — accuracy not yet measured
Section 6.3 (page unavailable) reports 4.6% fluconazole-resistant C. parapsilosis isolates in Latin America—not a rate much higher than the citing sentence’s stated US range of 4–10%. The section does not provide the claimed US rate or comparable rates for Japan and Western Europe. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Could not verifycites [120] Pfaller, 2011, J Clin Microbiol sourceExperimental — accuracy not yet measured
The Results and Discussion passages report susceptibility of Aspergillus species to itraconazole, posaconazole, and voriconazole; no page numbers are provided. Searches for C. parapsilosis, fluconazole, and the claimed regional resistance rates found no passage addressing that comparison. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Ibrexafungerp is currently only FDA approved as oral therapy for vulvovaginal candidiasis, although clinical trials for invasive candidiasis step-down therapy, refractory candidiasis, and C. auris are ongoing.149,156–159”
§ Epidemiology of Invasive Candidiasis > The Antifungal Pipeline for IC
What the sources say
- Partly supportedcites [149] Seiler, 2021, Curr Fungal Infect Rep sourceExperimental — accuracy not yet measured
The Ibrexafungerp section (Agents in Phase III Clinical Trials; page unavailable) describes oral ibrexafungerp in ongoing trials, and the References list a phase III study for vulvovaginal candidiasis. Our copy does not state that ibrexafungerp is FDA approved, or that vulvovaginal candidiasis is its only approved indication. (LLM, conf=0.83)
- Supportedcites [156] Hoenigl, 2021, Drugs source
The Ibrexafungerp section states that the FDA approved ibrexafungerp for oral use in patients with vulvovaginal candidiasis. Its Future Role subsection says other approvals were still expected, supporting the claim that this was its only FDA-approved use at the time covered by the paper. (LLM, conf=0.92)
- Supportedcites [157] Mccarthy, 2022, Drugs R D source
The Abstract states that the FDA approved ibrexafungerp for vulvovaginal candidiasis following trials of oral treatment. The Introduction identifies it as an oral formulation, while Future Directions treats other indications as under investigation rather than approved. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [158] Spec, 2019, J Antimicrob Chemother source
- Disputedcites [159] Jallow, 2021, J Fungi sourceExperimental — accuracy not yet measured
Section 8, “Indications and Usage,” says the FDA had accepted a new drug application for oral ibrexafungerp to treat vulvovaginal candidiasis; it does not say the drug was approved. Section 9, “Conclusions,” says an FDA action date was still pending and a US commercial launch was planned, contrary to the claim that approval had already been granted. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
90 more claims · 59 with their cited sources checked
Create a free account to see all 170 claims and to verify the 4 references still open.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 58
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Epidemiology of Invasive Candidiasis > Geographic Differences of Invasive Candidiasis
“to 2018 (21.4%)56”
§ Epidemiology of Invasive Candidiasis > Geographic Differences of Invasive Candidiasis
“| C. glabrata | 13.9% | 13.8% | 21.0% |”
Citations
Cites
Guidelines for the Prevention of Intravascular Catheter-related Infections
O'Grady, N. P., Alexander, M., Burns, L. A., Dellinger, E. P., Garland, J., Heard, S. O., Lipsett, P. A., Masur, H., Mermel, L. A., Pearson, M. L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir257 · Cited by 4,699
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · cited 6×
“125,164 C. auris outbreaks in healthcare facilities has recently seen an increase, greatly facilitated by the COVID pandemic with the large numbers of critically ill, mechanically ventilated patients and likely breaches in infection control practices.”
BackgroundInfluentialSelf-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“33 More recent data using US electronic medical records showed there was no significant change in the incidence between 2009–2017, with an overall incidence of inpatient IC of 90 per 100,000 hospitalizations.”
MethodDonnelly, J. P., Chen, S. C., Kauffman, C. A., Steinbach, W. J., Baddley, J. W., Verweij, P. E., Clancy, C. J., Wingard, J. R., Lockhart, S. R., Groll, A. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1008 · Cited by 2,917
Self-citationLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Self-citationGlobal incidence and mortality of severe fungal disease
Denning, D. W. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00692-8 · Cited by 1,640
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636 · cited 8×
“18,62,66 However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.”
BackgroundMethodInfluentialSelf-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“92 Less common species such as C. lusitaniae and C. guilliermondii have also been reported.”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Research works printed but not linked: 2
- Ulrych, 2020, Epidemiol Mikrobiol Imunol, 69, 57
- 2020, Clinical Practice of Medical Mycology in Asia
Cited by
Candida auris: Epidemiology Update and a Review of Strategies to Prevent Spread
Hayes, J. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226675 · Cited by 45
Biofilm Formation as a Pathogenicity Factor of Medically Important Fungi
Vila, T. V. M., & Rozental, S. (2016) · InTech eBooks · doi:10.5772/62768 · Cited by 30
Growth defects resulting from inhibiting ERG20 and RAM2 in Candida glabrata
Nakayama, H., Ueno, K., Uno, J., Nagi, M., Tanabe, K., Aoyama, T., Chibana, H., & Bard, M. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02205.x · Cited by 22
Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy
Martín‐Loeches, I., Cornely, O. A., Denning, D. W., Guinea, J., Bassetti, M., Maertens, J. A., Hoenigl, M., Kanj, S. S., Slavin, M. A., Ostrosky-Zeichner, L. L., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08151-1 · Cited by 23
Self-citationThe impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance
Kozubowski, L., & Berman, J. G. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf001 · Cited by 14
Candida auris : host interactions, antifungal drug resistance, and diagnostics
Chowdhary, A., Lionakis, M. S., & Chauhan, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00187-22 · Cited by 22
Motta, J. C., Rivas-Pinedo, P., & Oñate, J. (2025) · Journal of Fungi · doi:10.3390/jof11090609 · Cited by 14
“In the United States, the incidence is 8.7 cases per 100,000 people, with an associated mortality rate of 36% [39].”
InfluentialHuang, S., Song, Y., Lv, G., Liu, J., Zhao, J., Wang, L.-L., & Xiang, M.-J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1550894 · Cited by 13
“However, in the past decade, the contribution of non -C. albicans Candida species (NCACs) to IC has increased (Bays et al., 2024; Salimi et al., 2024).”
Singh, S., Youssef, E. G., Barbarino, A. M., Hautau, H., Nabeela, S., Gebremariam, T., Alkhazraji, S., Ostroff, G. R., Christensen, D., Cochrane, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32488-8 · Cited by 10
Maharaj, A. R., Zelenitsky, S. A., & Vercaigne, L. M. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00279.x · Cited by 10
De-la-Pinta, I., Marcos‐Arias, C., Sevillano, E., Eraso, E., & Quindós, G. (2026) · Microorganisms · doi:10.3390/microorganisms14020367 · Cited by 7
Sirota, S. B., Bender, R. G., Dominguez, R.-M. V., Vongpradith, A., Movo, A., Swetschinski, L. R., Araki, D. T., Han, C., Wool, E. E., Jabbar, A. A. J., et al. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(26)00101-8 · Cited by 12
Mandatory surveillance of bacteremia conducted by automated monitoring
Mølbak, K., Andersen, C. Ø., Dessau, R. B., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1502739 · Cited by 6
Candida vulturna , the Next Fungal Menace? A Narrative Review
Harchand, R., Spruijtenburg, B., Meijer, E. F. J., de Groot, T., Rudramurthy, S. M., & Meis, J. F. G. M. (2025) · Mycoses · doi:10.1111/myc.70070 · Cited by 7
Cugnata, S., Sacheli, R., Layios, N., & Hayette, M. (2025) · Journal of Fungi · doi:10.3390/jof11060465 · Cited by 8
Khalaf, H. Y., Nasr, F. B., Noomi, B. S., Mnif, S., & Aifa, S. (2025) · Microbiology Research · doi:10.3390/microbiolres16080178 · Cited by 8
“Invasive candidiasis (IC), albeit less common than staphylococcal infections, is characterized by higher fatality rates, greater associated expenditures, and prolonged patient hospitalization [3,4].”
Walter, J.-C., Kissmann, A., Gruber, D., Alpízar-Pedraza, D., Martell-Huguet, E. M., Preising, N., Rodríguez, A., Ständker, L., Kleber, C., Knoll, W., et al. (2025) · Biomolecules · doi:10.3390/biom15030322 · Cited by 9
The Antifungal Effects of Equol Against Candida albicans Involve Mitochondrial Dysfunction
Ge, A., Zhou, H., Yang, X., Zhao, C., Xin, C., & Song, Z. (2025) · Journal of Fungi · doi:10.3390/jof11050339 · Cited by 6
“Typically, C. albicans accounts for about 40–60% of Candida isolates from hospitalized patients [7,8].”
Şumlu, E., Aydın, M., Korucu, E. N., Öztürk, A., & Emsen, B. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107106 · Cited by 4
Gentile, P., Ragusa, E., Bruno, R., Ceccarelli, F., Adani, C., Bolletta, E., Simone, L. D., Gozzi, F., & Cimino, L. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2524013 · Cited by 8
Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives
Slepčanová, H., Dobiáš, R., Langer, A. B. S., Káňová, M., & Hamal, P. (2025) · Mycopathologia · doi:10.1007/s11046-025-01035-4 · Cited by 5
Harrington, A. A., Nickels, T. J., & Cunningham, K. W. (2026) · mBio · doi:10.1128/mbio.02546-25 · Cited by 4
A Review of Current Insights in Fungal Endocarditis
Akritidou, O., Peristeri, A.-M., Lymperatou, D., Prokopidou, A., Christaki, E., & Nikopoulou, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176149 · Cited by 10
“Echocardiography is recommended in patients with persistent candidemia to assess for fungal endocarditis [22].”
InfluentialPariano, M., Puccetti, M., Fabi, C., Nunzi, E., Balucchi, S., Perioli, L., Ricci, M., Giovagnoli, S., Garaci, E., & Romani, L. R. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2569831 · Cited by 7
Cai, G., & Zhang, Z. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01617-25 · Cited by 5
Ünal, N., Karakoyun, A. S., Ünal, İ., Turunç, T., Lass‐Flörl, C., & İlkit, M. (2025) · Journal of Fungi · doi:10.3390/jof11110788 · Cited by 8
“Many other studies have shown that C. albicans has a high sensitivity profile to antifungals, with resistance to FLC generally remaining below 5% [19,63–65].”
Sang, Q.-Y., Liao, Y.-H., Huang, K., Xie, Y.-R., Yao, Y., Chen, P., & Liang, X. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002011 · Cited by 3
Dellai, F., Pagotto, A., Sbrana, F., Ripoli, A., Danieli, G., Colombo, A. E., D’Elia, D., Geminiani, M., Giuliano, S., Sartor, A., et al. (2025) · Journal of Fungi · doi:10.3390/jof11050400 · Cited by 3
“Both in-hospital and 30-day mortality rates have remained consistently high, at approximately 50%, throughout the fourteen-year analysis period [Table 3].”
Antifungal Susceptibility and Resistance-Associated Gene Expression in Nosocomial Candida Isolates
Hernandez-Reyes, F. B., Muñoz-Miranda, L. A., Kirchmayr, M. R., Ortiz‐Lazareno, P. C., Cortés-Zárate, R., Iñíguez-Moreno, M., Jacobo-Cuevas, H., & Nava-Valdivia, C. A. (2025) · Journal of Fungi · doi:10.3390/jof11120895 · Cited by 5
“Globally, the epidemiology of nosocomial candidiasis is evolving, while C. albicans remain predominant, non-albicans Candida (NAC) species are increasingly implicated in bloodstream and invasive infections [31].”
Novy, E., Esposito, M., Debourgogne, A., & Roger, C. (2025) · Journal of Fungi · doi:10.3390/jof11020091 · Cited by 5
“Candida albicans is the most frequently isolated species [8].”
Candida albicans gastrointestinal colonization resistance: a host-microbiome balancing act
Bays, D. J., & Savage, H. P. (2025) · Infection and Immunity · doi:10.1128/iai.00610-24 · Cited by 7
Self-citationManagement of invasive candidiasis in French ICUs: insights from a 2024 nationwide survey
Esposito, M., Lemery, F., Agrinier, N., Soudant, M., Charmillon, A., Degand, N., Dorin, J., Dellamonica, J., Morand, L., Roger, C., et al. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05169-7 · Cited by 3
Emery, C. L., Dhiman, N., Chow, S.-K., Peterson, G., Granato, P. A., Bernier, B., & Farhang, J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00362-25 · Cited by 4
Relevante Aspekte zu Candida-Spezies in der Dermatologie: Eine Übersicht
Müller, V. L., Kreuter, A., Uhrlaß, S., & Nenoff, P. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05538-5 · Cited by 3
Muñiz-Bernal, V., Ríos-López, A. L., Treviño‐Rangel, R. D. J., Becerril-García, M. A., Torres, Á. A., & Flores-Maldonado, O. E. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.108121 · Cited by 2
Exploration of piperazine-azole hybrids as antifungal agents against drug-resistant Candida albicans
Xu, Z., Zhang, X. L., Wei, Y., Li, A., Mao, Z., & Wang, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109181 · Cited by 2
Badrane, H., Clancy, C. J., & Nguyen, M. H. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01545-25 · Cited by 2
Bagon, N. P., Marques, V. D., Ferreira, D. G., & Negri, M. (2026) · Life · doi:10.3390/life16010148 · Cited by 3
“Given that 60% to 70% of nosocomial infections are associated with such devices, where colonization frequently precedes recurrent infectious processes, understanding the intrinsic biofilm-forming capacity of NAC species under host-mimicking conditions is vital [1,19,25].”
Ren, Y., Qin, J., Li, M., & Shen, F. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c07370 · Cited by 2
Angelini, J., Ferin, S., Martini, L., Flammini, S., Tascini, C., & Giuliano, S. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-25 · Cited by 2
Caracciolo, M., D’Aleo, F., Stagno, M. F., Papola, C., Pellicano, S., Nicolò, G. M., Caracciolo, S. A., Ripepi, A., Pellicano, N., Scopelliti, C., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1796594 · Cited by 2
Zheng, Z., Li, Z., Yu, M., Ma, X., Gao, J., Wang, Y., Wu, J., Yu, X., Ma, Y., & He, X. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2544687 · Cited by 3
Lim, W. J., Lee, B., Farrington, Z., Alhaija, A. A. A., Fleming, A. B., Sullivan, D. J., & Moran, G. P. (2025) · Microbiology · doi:10.1099/mic.0.001594 · Cited by 2
“Multiple factors have been identified that may contribute to the increased incidence of azole-resistant C. albicans , such as the wide and long-term usage and the fungistatic nature of azole drugs [1, 2].”
Temporal changes in fungal epidemiology in ICU post-operative peritonitis cases
Montravers, P., Bonnal, C., Andrei, S., Augustin, P., Grall, N., & Zappella, N. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05314-2 · Cited by 1
Candida krusei Lung Abscess With Black Necrotic Aspirate
Ing, S. K., Lau, P. Y., & Ngu, N. H. (2026) · Respirology Case Reports · doi:10.1002/rcr2.70460 · Cited by 1
Kulig, K., Zuzanna, M., Kowalik, K., Michalina, M., Bednarek, A., Satała, D., Juszczak, M., Łabędzka-Dmoch, K., Woźnicka, O., Pyza, E., et al. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04713-z · Cited by 1
Suleyman, G., & Alangaden, G. J. (2026) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2026.02.008 · Cited by 2
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 3
Rivera-Yañez, N., Hernández-Sánchez, K. M., Hernández-Rosas, N. A., Francisco-Cruz, L., Nieto-Yáñez, Ó., Ortega, C. C. B., Pozo‐Molina, G., Méndez-Catalá, C. F., Méndez‐Cruz, A. R., Ruiz-Hurtado, P. A., et al. (2026) · Journal of Fungi · doi:10.3390/jof12050301 · Cited by 1
“In recent years, an increase in infections caused by non-albicans Candida species has been observed, with an increase in invasive candidiasis of up to 7% across Europe [25].”
Zhao, Y., Dai, R., Liu, F., Liu, K. Q., Kang, W., Zhang, G., Li, J., Zhang, J., Wang, T., Gao, H., et al. (2026) · Emerging Microbes & Infections · doi:10.1080/22221751.2026.2695535 · Cited by 1
Galassi, L., Magrin, N., Pieri, F., Crivelli, B., Banfı, C., & FAITELLI, B. (2026) · Hospital Pharmacy · doi:10.1177/00185787261470599 · Cited by 1
Cryo-EM structures of Candida albicans chitin synthase Chs1 reveal a druggable translocation channel
Ren, Z., Chhetri, A., Liu, C., Guan, Z., Offner, S., Kozhanov, D., Borgnia, M. J., Im, W., Yokoyama, K., & Lee, S. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02485-2 · Cited by 1
Rivas-Pinedo, P., Motta, J. C., & Oñate, J. (2025) · Journal of Fungi · doi:10.3390/jof11080583 · Cited by 3
“In the region, C. parapsilosis has increased in frequency to 25–30%, especially in neonatal and pediatric ICUs [8,60].”
InfluentialZhang, X., Zheng, C., Ge, W., Li, X., Wang, X., Sun, Y., & Wu, X. (2025) · PeerJ · doi:10.7717/peerj.18961
Sirota, S. B., Bender, R. G., Hay, S. I., Murray, C. J. L., Naghavi, M., & Kyu, H. H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5355367
Şevik, F., Ulukan, H., Hasanlı, R., Algın, S., Martlı, H. F., Kılıç, E., Erganiş, S., Şahin, E. A., Bozdayı, G., Tunçcan, Ö. G., et al. (2025) · ANKEM Dergisi · doi:10.54962/ankemderg.1723646 · Cited by 2
Marchenko, O., Коваль, Т. І., Bodnar, V. A., Pryimenko, N. O., & Ізюмська, О. М. (2025) · Ukrainian Dental Almanac · doi:10.31718/2409-0255.3.2025.06
A Retrospective Study of Invasive Candidiasis in a Tertiary Teaching Hospital
Dave, P., Mishra, I., & Bhatia, G. (2025) · Cureus · doi:10.7759/cureus.96913
“This was consistent with recent data from 2024-2025 demonstrating that invasive candidiasis is no longer dominated by Candida albicans as non-albican species were more commonly isolated [6-7].”
Pawar, K., & Singh, A. K. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002083 · Cited by 1
Zhao, Y. Y., Wang, H., Yu, J., Li, Y., Zhang, G., Kang, W., Xiao, M., Yang, Q., Guo, L., & Xu, Y. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02608-25
Epidemiology and Management of Antifungal-Resistant Bloodstream Infections in Healthcare Settings
Sayyouh, O. (2025) · Infectious diseases · doi:10.5772/intechopen.1012710 · Cited by 1
Jabrodini, A., Zareshahrabadi, Z., Khorram, M., Asadian, F., Jafari, M., Iraji, A., & Zomorodian, K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149362 · Cited by 1
Smart nanotherapeutics against chronic infections
Kumar, A., Singh, A. K., Verma, I. K., Keshri, A., Chauhan, G., Agrawal, S., Ratn, A., Dhakad, M. S., & Sharma, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33070-4.00011-3
Tuan, D. A., & Masák, J. (2026) · Journal of Applied Microbiology · doi:10.1093/jambio/lxag015 · Cited by 1
Novy, E., Schaeffer, A., Nguyen, M., Dalle, F., Pottecher, J., Letscher‐Bru, V., Louis, G., Stephan, C., Luc, A., Machouart, M., et al. (2026) · Critical Care · doi:10.1186/s13054-026-05882-5
Gökmen, R., Erdoğan, A., & Cunetoglu, B. (2026) · Cureus · doi:10.7759/cureus.107778
“For instance, the East Asian Clade is generally less resistant and has shown more limited spread compared to other clades, whereas the South Asian Clade and the South American Clade have disseminated across broader geographic areas [34].”
Feng, W., Wang, X., Feng, G., & Liu, G. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53104
Zaragoza, R., Estella, Á., Nuvials, X., Robles-Plaza, M., & Gómez, A. C. (2026) · Journal of Fungi · doi:10.3390/jof12050339 · Cited by 1
“However, the proportion of non-albicans Candida spp. as the main causative agent has increased [39,40].”
InfluentialA fungal hemophore relay mediates heme transfer via transient protein interactionsPreprint
Roy, U., Far, E., Chattopadhyay, S., Weissman, Z., & Kornitzer, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.08.723727
Torabi, I., Shams‐Ghahfarokhi, M., Amaechi, B. T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9466640/v1
Любимова, А. В., Аlekseev, A. Y., Vasilyeva, N. N., Bogomolova, T. S., Borzova, Y. V., Lebedeva, E. A., & Mokhov, A. S. (2026) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2026-26-2-112-123
Nyamessameye, D., Piron, M., Barry, A., Mohammed, S., Seyll, E., & Martiny, D. (2026) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-026-05534-0
Yang, J., Feng, W., Xie, M., Yu, D., Yang, W., Ma, Y., & Xi, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1817039
“%) among critically ill patients, posing a significant challenge to modern healthcare systems (4).”
Barone, S., Mateu, B., Piccolo, M., Guadagni, A., Irace, C., Lembo, F., Summa, V., Buommino, E., & Brindisi, M. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00195 · Cited by 2
Madrid, A. M., Fuentes, B., Araneda, C., Montenegro, I., Caro, N., Silva, V., & Muñoz, E. (2026) · Pharmaceuticals · doi:10.3390/ph19050759
“The 2Y7L receptor corresponds to the N-terminal adhesive domain of Als9-2, a member of the ALS family involved in host adhesion, colonization, and biofilm development [1,6].”
Parente, E., Pietrafesa, R., Romano, V. A., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6869044
Schröter, I., Schindler, D., Morath, C. P., Renders, L., Andrassy, J., Kanzelmeyer, N., Schork, A., Zeier, M., Giese, T., Sommerer, C., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13558-2 · Cited by 1
Yang, M., Yu, Q., Xu, Y., et al. (2026) · Arabian Journal of Chemistry · doi:10.25259/ajc_454_2025
Amengor, C. D. K., Biniyam, P. D., Gyan, P., Harley, B. K., Neglo, D., Quansah, P., Ohene‐Adu, V., Adu-Adjei, K., Osei, M., Amengor, C. M., et al. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100447
Harley, B. K., Opoku, M., Asamoah, T. D., Mantey, A. E., Ben, I. O., Jato, J., Aggrey, M. O., Kortei, N. K., & Fleischer, T. C. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103590
Smâdu, S., Tetradov, S. C., Popescu, C. P., Nica, M., Oprisan, C., Ene, L., & Florescu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12070482
“…international guidelines; however, in these critically ill, intensive-care-dependent patients, the removal of indwelling central venous catheters was frequently not feasible, and the documented antifungal resistance may have further contributed to the persistence of bloodstream infection [9,46].”
Akindele, A., Erinle, B., Oyedeji, B., & Adebolu, T. T. (2026) · Biomedical Sciences · doi:10.11648/j.bs.20261202.13
From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression
Jerez, J. R., Ambrosio, M. V., Fernandes, M. E. O., & Mima, E. G. D. O. (2026) · MicrobiologyOpen · doi:10.1002/mbo3.70353 · Cited by 1
Clinical controversies in the management of candidemia in adults and children
Cluck, D. B., White, B. P., Hilzendager, S. A., Ryder, J. H., Tu, P. J., McPherson, A. Z., Rogers, D. J., & Chastain, D. B. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag212
Katsiari, M., Nikolaou, C., Theodoridou, K., Palla, E., Tsakris, A., & Vrioni, G. (2026) · Pathogens · doi:10.3390/pathogens15070734
“Among NAC species, C. auris and fluconazole-resistant C. parapsilosis represent major nosocomial threats due to their ability to persist in healthcare environments and to cause outbreaks, in combination with antifungal resistance patterns [32,33].”
da Rocha, I. F. M., Ennis, C. L., Romagnoli, B. A. A., Almeida, K. S., Rossi, S. A., da Costa, A. T., de Oliveira, H. C., Nobile, C. J., & Alves, L. R. (2026) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2026.100645
Ramírez-Trujillo, R. A., Hernández, P. C., & González, Á. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354684
Pinheiro, D. R. S., Barbosa, S. A., de Oliveira, L. C., Cabral, V. P. D. F., Rodrigues, D. S., da Costa, É. R. M., Silveira, M. J. C. B., Moreira, L. E. A., Cavalcanti, B. C., Magalhães, I. L., et al. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108735 · Cited by 1
Campa, I. C., Studebaker, M. C., Henao‐Martínez, A. F., Kršák, M., & Chastain, D. B. (2026) · Medical Mycology · doi:10.1093/mmy/myag080
Kumar, S., Singh, Y., Sharma, G. C., Singh, A., Shukla, S. K., Kanojiya, S., & Banerjee, D. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100835
Rodrigues, L. S., Barbosa, S. D. C., Chacon, A. P. S., Siqueira, A. C., Bernardi, G., Pillonetto, M., Vicente, V. A., Arend, L. N. V. S., Svidzinski, T. I. E., & Dalla-Costa, L. M. (2026) · Mycopathologia · doi:10.1007/s11046-026-01095-0
Mboowa, G., Sserwadda, I., Kanyerezi, S., Kidenya, B. R., Jonani, B., & Musinguzi, B. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1896572
“Candida spp. are important causes of mucosal and invasive fungal disease, with candidemia and invasive candidiasis associated with substantial morbidity, mortality, prolonged hospitalization, and health-system burden (Bays et al., 2024; Denning, 2024).”
Valverde-Urrea, M., Defez-Perez, J., Colom, M. F., Terradas, M., Lopez-Llorca, L. V., & Lopez‐Moya, F. (2026) · Marine Drugs · doi:10.3390/md24090296
“C. auris has been reported in more than 30 countries and is associated with high mortality rates and environmental persistence, which facilitates horizontal transmission [8,12,13].”
Achilonu, C. C. (2026) · Drugs and Drug Candidates · doi:10.3390/ddc5030047 · Cited by 2
Parente, E., Pietrafesa, R., Romano, V. A., Labella, M. G., & Ricciardi, A. (2026) · Food Microbiology · doi:10.1016/j.fm.2026.105282
An Interaction Domain Drives Heme Exchange in the C. albicans CFEM Hemophores Cascade
Roy, U., Far, E., Chattopadhyay, S., Weissman, Z., & Kornitzer, D. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169997
Kılıç, A., & Palavecino, E. L. (2026) · Cureus · doi:10.7759/cureus.115734
“Although incidence declined after the early 2000s, more recent surveillance demonstrates a plateau and stabilization between 2009 and 2017 across US sites [10].”
Gómez-Gaviria, M., Ramírez-Sotelo, U., & Mora-Montes, H. M. (2026) · Current Clinical Microbiology Reports · doi:10.1007/s40588-026-00278-z
Gómez-Gaviria, M., Baruch-Martínez, D. A., & Mora-Montes, H. M. (2026) · Microorganisms · doi:10.3390/microorganisms14092038
“In recent decades, the epidemiology of invasive candidiasis has shifted from infections predominantly caused by C. albicans toward a growing participation of non-albicans Candida species [122,123].”
Anitua, E., Tierno, R., & Alkhraisat, M. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1901254
“Infectious dermatoses such as Herpes simplex infection, candidiasis, impetigo, and syphilis constitute a substantial global health burden due to their high prevalence, chronic or recurrent nature, and associated psychosocial and economic consequences (88–91).”
Metadata
- Authors
- Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G.
- Affiliations
- University of California Davis Medical Center (US)
- Centers for Disease Control and Prevention (US)
- The University of Texas Health Science Center at Houston (US)
- Medical University of Graz (AT)
- University of Alabama at Birmingham (US)
- Corresponding author
- Bays, Derek
- ORCID
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2024-08
- Volume
- Volume 16
- Pages
- 549-566
- ISSN
- 1179-1349 (ISSN-L)
- PMC
- PMC11366240
- OpenAlex
- W4401967436
- Cited by
- 109
- References
- 165
- Citations by year
- 2026: 62 · 2025: 42 · 2024: 2
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Epidemiology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (UL1TR001860, KL2TR001859)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- invasive candidiasis, Candida albicans, non-albicans Candida, Candida auris, antifungal resistance, opportunistic fungal infection, emerging fungal pathogens, antifungal agents, nosocomial transmission, cancer patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
